Drug Trial Radar · NCT05161390
Study of LM-302 in Patients With Advance Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Nov 26, 2021
Primary completion
Jan 10, 2025
Study completion Jan 10, 2025
Sponsor
- Lead sponsor
- LaNova Medicines Zhejiang Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
Interventions
LM-302 InjectionDrug
LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: Cycle 1 of each cohort. Duration of one cycle is 21 days
- Adverse Events and Serious Adverse EventsTime frame: From signing the ICF until 28 days after EOT or accept other anti-cancer therapy
- Recommended Phase II Dose (RP2D)Time frame: up to 21 days following first dose
- Maximum Tolerated Dose (MTD)Time frame: up to 21 days following first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.